Ustekinumab

Human IgG1 kappa

Immobilized IL-12 beta Protein, Human (HEK293, Fc, HY-P73160) can bind Ustekinumab. The EC₅₀ for this effect is 13.6 ng/mL.

Flow cytometric analysis of 1×10⁶ Jurkat cells labelling IL-12B (red) with Ustekinumab (HY-P9909). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Customer Validation
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. Daily change in body weight for each group, including Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Measurements of colonic tissue length in various groups on day 10. DAI changes throughout 10 days, calculated as the total of the stool consistency (0–3), fecal bleeding (0–4), and weight loss (0–4) indexes.

Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Customer Validation
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Mice colonic sections stained with HE on day 10 following the indicated treatments.

Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Customer Validation
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Colonic MPO levels on day 10.) Colonic TNF-α, IL-6, and IL-1β levels on day 10.

Ustekinumab purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2021 Sep;22(9):1107-1117. [Abstract]

Customer Validation
Flow cytometry quantification of cell viability and lipid ROS of HC neutrophils cultured in vitro with 20% SLE serum supplemented with anti-CXCL11 (0.1, 1, 5 µg/ml) or Ustekinumab (0.1, 1, 10 µg/ml) for 16 hours.